Market Cap | 8.52B | P/E | 52.74 | EPS this Y | -12.70% | Ern Qtrly Grth | -39.80% |
Income | 122.56M | Forward P/E | 42.33 | EPS next Y | 16.40% | 50D Avg Chg | 5.00% |
Sales | 1.09B | PEG | 8.02 | EPS past 5Y | -1.19% | 200D Avg Chg | 38.00% |
Dividend | N/A | Price/Book | 8.08 | EPS next 5Y | 4.18% | 52W High Chg | -6.00% |
Recommedations | 1.90 | Quick Ratio | 1.13 | Shares Outstanding | 49.56M | 52W Low Chg | 135.00% |
Insider Own | 2.04% | ROA | 5.31% | Shares Float | 48.44M | Beta | 0.59 |
Inst Own | 109.58% | ROE | 10.31% | Shares Shorted/Prior | 3.68M/4.82M | Price | 32.17 |
Gross Margin | 28.86% | Profit Margin | 11.27% | Avg. Volume | 313,087 | Target Price | 26.78 |
Oper. Margin | 12.60% | Earnings Date | Aug 6 | Volume | 289,978 | Change | -2.72% |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Citigroup | Buy | Aug 7, 24 |
Morgan Stanley | Equal-Weight | Jul 15, 24 |
Morgan Stanley | Equal-Weight | Apr 22, 24 |
Stephens & Co. | Overweight | Mar 25, 24 |
Morgan Stanley | Equal-Weight | Nov 1, 23 |
Jefferies | Hold | Nov 1, 23 |
Stephens & Co. | Overweight | Sep 26, 23 |
CJS Securities | Market Outperform | Sep 19, 23 |
Keybanc | Overweight | Aug 30, 23 |